Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Mark G. Kris's publication output changed over time?
ScholarIQpublication output · 2003–2018
Output grew0% over the shown period — from 1 works in 2003 to 1 in 2018.
1
1
3
1
1
2
1
1
1
200320042005200820132014201520172018
What are the most-cited papers on Mark G. Kris?
ScholarIQmost cited works
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
William Pao, Vincent A. Miller, Maureen F. Zakowski, Jennifer A. Doherty, Katerina Politi, Inderpal S. Sarkaria, Bhuvanesh Singh, Robert T. Heelan, Valerie W. Rusch, Lucinda A. Fulton, Elaine R. Mardis, Doris M. Kupfer, Richard K. Wilson, Mark G. Kris, Harold Varmus
Proceedings of the National Academy of Sciences. 20044,354 CitationsOPEN ACCESS
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William Pao, Vincent A. Miller, Katerina Politi, Gregory J. Riely, Romel Somwar, Maureen F. Zakowski, Mark G. Kris, Harold Varmus
PLoS Medicine. 20053,538 CitationsOPEN ACCESS
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
Ethan Basch, Allison M. Deal, Mark G. Kris, Howard I. Scher, Clifford A. Hudis, Paul Sabbatini, Lauren J. Rogak, Antonia V. Bennett, Amylou C. Dueck, Thomas M. Atkinson, Joanne F. Chou, Dorothy Dulko, Laura Sit, Allison Barz Leahy, Paul J. Novotny, M. Fruscione, Jeff A. Sloan, Deborah Schrag
Journal of Clinical Oncology. 20152,682 CitationsOPEN ACCESS
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, T. J. Lynch, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, H. Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael Wolf, Steven D. Averbuch, Judith Ochs, Andrea Kay
JAMA. 20032,541 Citations
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, Maureen F. Zakowski, William Pao, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Gregory J. Riely
Clinical Cancer Research. 20132,497 CitationsOPEN ACCESS
Related on ScholarIQ
Memorial Sloan Kettering Cancer Center
Institution
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Paper
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Paper
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
Paper
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
Paper
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Paper